Answers are grounded in this paper and cite their sources.
Mycobacterium tuberculosis, the causative agent of tuberculosis, remains one of the world’s leading causes of death. The emergence of multidrug-resistant and extensively drug-resistant strains has stressed the urgent need for new second-line antimycobacterial agents that compensate for resistance to front-line drugs (isoniazid, rifampin, ethambutol, and pyrazinamide). Glutamine synthetase is a promising target that is essential for nitrogen metabolism in vitro and in vivo. M. tuberculosis expresses four GS homologues encoded by the glnA1-A4 genes, but only glnA1 is required for growth in culture and survival in the host. GlnA1 functions inside the bacterial cell in addition to being secreted to function extracellularly. Inhibition of extracellular glutamine synthetase by methionine sulfoximine was synergistic with isoniazid in clearing infection in guinea pigs. However, the activity of glutamine synthetase inhibitors is limited by their inability to penetrate the waxy mycomembrane. We designed di- and tripeptide prodrug formulations of three glutamine synthetase inhibitors, methionine sulfoximine, glufosinate, and tabtoxinine-β-lactam, to enable access of the inhibitors to cytoplasmic GlnA1 via peptide permeases followed by peptidase cleavage in the cytoplasm. The peptide prodrug formulations inhibited M. tuberculosis growth and biofilm formation in culture. Prodrug treatment depleted cellular l-Gln as determined by targeted metabolomic analysis and growth inhibition effects were reversed by supplementation with l-Gln, together indicating effective targeting of the intrabacterial GlnA1 enzyme. Methionine sulfoximine, glufosinate, and tabtoxinine-β-lactam feature three distinct ‘warheads’ (sulfoximine, phosphinate, 3-hydroxy-β-lactam, respectively) appended to an l-Glu backbone. The Kitz–Wilson model was used to evaluate the time-dependent inhibition kinetics of Mtb GlnA1 for the three GS inhibitors. A general trend of inhibitor efficiency of phosphinate > 3-hydroxy-β-lactam ≫ sulfoximine was observed to correlate with the potency of growth inhibition in culture by prodrugs. Collectively, the findings in this study support that inhibition of intrabacterial GlnA1 in Mtb can be achieved via di- and tripeptide prodrug formulations of glutamate antimetabolites, thus representing an attractive therapeutic strategy for treating tuberculosis infections.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: